NTT-LTD.
18.5.2023 14:01:25 CEST | Business Wire | Press release
NTT Ltd., a leading IT infrastructure and services company, and Cisco, a worldwide leader in technology, today announced a collaboration to develop and deploy joint solutions that empower organizations to improve operational efficiencies and advance sustainability goals.
Leveraging NTT’s Edge as a Service portfolio and Cisco’s IoT capabilities, solutions developed by the two companies will offer real-time data insights, enhanced security, improved decision-making, and reduced operational costs through predictive maintenance, asset tracking, and supply chain management capabilities.
The companies will deliver solutions that combine NTT’s Managed Services expertise, automation capabilities at the edge, and the management of complex IT environments, with Cisco’s IoT capabilities, including Low Power Wide Area Networking (LoRaWAN).
As part of today’s news, NTT has bolstered its IoT consulting and services business that brings together more than 1000 practitioners and 100 use cases in areas such as connected cars, fleet management, predictive maintenance, smart cities, digital twins, connected factories, utilities and more. NTT has already trained more than 500 Cisco sales experts to accelerate the companies’ combined capabilities and go-to-market efforts.
“We are accelerating our IoT business initiatives to deliver a powerful portfolio of repeatable services that can be tailored to meet customer demand for these kinds of solutions. We’re in a unique position,” said Devin Yaung, SVP of Group Enterprise IoT Products and Services at NTT.
“We are excited to work together to help transition our customers to this IoT-as-a-Service model so they can quickly realize the business benefits across industries and around the globe,” said Samuel Pasquier, VP of Product Management, Industrial IoT Networking, Cisco.
Transforming Water Management Through Smart Solutions
NTT and Cisco are developing solutions and go-to-market offers focusing on industries such as manufacturing, transportation, and healthcare, where there is a growing demand for edge computing and IoT solutions. The two companies are already deploying this advanced ‘ruggedized’ service to several customers including Compagnie Intercommunale Liégeoise des Eaux (CILE), a public water distribution company located in Belgium.
NTT and Cisco have deployed thousands of LoRaWAN sensors across CILE’s infrastructure to provide remote visibility that improves operational efficiencies related to water quality, consumption, distribution, and maintenance. The solution also includes advanced technologies such as smart distribution networks, remote reading through smart meters, smart grid for remote management, connected IoT objects, and AI, delivered as a managed service. The network also provides the building blocks to support other sustainability use cases such as waste management, parking management, water quality and street light controls.
“At CILE, we provide critical infrastructure for 24 cities in Belgium, which means efficiency, security and reliability are key," said William de Angelis, CIO and CDO at CILE. “With NTT and Cisco’s support, we have real-time insights into our facilities and distribution networks, including faster detection of leaks, allowing us to respond to issues instantaneously and expand the network to other sustainability use cases.”
NTT Ramps Up IoT Consulting and Services Business
In a move to prioritize and scale IoT for clients and partners, NTT has activated an IOT-dedicated business unit bringing together deep expertise and capabilities from around the globe. The team of 1,000 consultants, engineers, enterprise architects, and sustainability experts will build, deploy, and manage more than 100 use cases in areas such as connected cars, fleet management, predictive maintenance, smart cities, digital twins, connected factories and more.
“We’re doubling down on NTT’s IoT capabilities to meet customer demand,” continued Yaung. “What we’re doing is pulling together our collective knowledge and skillsets, and putting the full power of NTT behind it, to better service our customers and the increasing need to outfit or retrofit their organizations with the connectivity and visibility they need to improve day-to-day business operations.”
The global IoT market is expected to grow 19 percent in 2023, with a potential market size of $483 billion by 2027.
#ENDS#
About NTT Ltd.
As part of NTT DATA, a USD 30 billion IT services provider, NTT Ltd. is a leading IT infrastructure and services company serving 65% of the Fortune Global 500 and more than 75% of the Fortune Global 100. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments where networks, cloud and applications converge. We offer tailored infrastructure and ensure consistent best practices in design and operations across all of our secure, scalable and customizable data centers. On the journey towards a software-defined future, we support organizations with our platform-delivered infrastructure services. We enable a connected future.
Visit us at services.global.ntt
About Cisco
Cisco (NASDAQ: CSCO) is the worldwide leader in technology that powers the Internet. Cisco inspires new possibilities by reimagining your applications, securing your data, transforming your infrastructure, and empowering your teams for a global and inclusive future. Discover more on The Newsroom and follow us on Twitter at @Cisco.
Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005431/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom